Sino Biopharmaceutical Past Earnings Performance
Past criteria checks 1/6
Sino Biopharmaceutical's earnings have been declining at an average annual rate of -9.7%, while the Pharmaceuticals industry saw earnings growing at 5.9% annually. Revenues have been growing at an average rate of 5.3% per year. Sino Biopharmaceutical's return on equity is 12.1%, and it has net margins of 7.1%.
Key information
-9.7%
Earnings growth rate
-9.6%
EPS growth rate
Pharmaceuticals Industry Growth | 5.6% |
Revenue growth rate | 5.3% |
Return on equity | 12.1% |
Net Margin | 7.1% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
What Does The Future Hold For Sino Biopharmaceutical Limited (HKG:1177)? These Analysts Have Been Cutting Their Estimates
Apr 03Sino Biopharmaceutical Limited's (HKG:1177) Intrinsic Value Is Potentially 34% Above Its Share Price
Mar 20Sino Biopharmaceutical Limited's (HKG:1177) Shares May Have Run Too Fast Too Soon
Dec 18Does Sino Biopharmaceutical (HKG:1177) Have A Healthy Balance Sheet?
Dec 02Sino Biopharmaceutical Limited (HKG:1177) Shares Could Be 41% Below Their Intrinsic Value Estimate
Nov 17We Think Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt With Ease
Aug 30Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 50% Undervaluation?
May 26Sino Biopharmaceutical (HKG:1177) Has A Rock Solid Balance Sheet
Apr 20Is Sino Biopharmaceutical Limited (HKG:1177) Trading At A 38% Discount?
Feb 09Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 41% Undervaluation?
Nov 11Sino Biopharmaceutical (HKG:1177) Seems To Use Debt Quite Sensibly
Oct 24Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 46% Undervaluation?
Jul 08Is Sino Biopharmaceutical (HKG:1177) Using Too Much Debt?
Apr 28An Intrinsic Calculation For Sino Biopharmaceutical Limited (HKG:1177) Suggests It's 45% Undervalued
Jan 22Sino Biopharmaceutical (HKG:1177) Has A Pretty Healthy Balance Sheet
Dec 03Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 41% Undervaluation?
Oct 19Sino Biopharmaceutical (HKG:1177) Has Re-Affirmed Its Dividend Of HK$0.02
Sep 03These 4 Measures Indicate That Sino Biopharmaceutical (HKG:1177) Is Using Debt Reasonably Well
Aug 27Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 38% Undervaluation?
Jul 14Revenue & Expenses BreakdownBeta
How Sino Biopharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 26,199 | 1,847 | 11,067 | 0 |
30 Jun 23 | 28,864 | 1,881 | 12,074 | 0 |
31 Mar 23 | 28,822 | 2,212 | 12,319 | 0 |
31 Dec 22 | 28,780 | 2,544 | 12,564 | 0 |
30 Sep 22 | 28,241 | 5,296 | 12,705 | 0 |
30 Jun 22 | 27,701 | 8,049 | 12,846 | 0 |
31 Mar 22 | 27,215 | 13,655 | 12,669 | 0 |
31 Dec 21 | 26,861 | 14,608 | 12,704 | 0 |
30 Sep 21 | 26,129 | 12,465 | 12,718 | 0 |
30 Jun 21 | 25,353 | 10,011 | 12,754 | 0 |
31 Mar 21 | 24,668 | 3,809 | 12,198 | 0 |
31 Dec 20 | 23,647 | 2,771 | 11,629 | 0 |
30 Sep 20 | 23,039 | 2,302 | 11,254 | 0 |
30 Jun 20 | 24,354 | 2,558 | 11,490 | 0 |
31 Mar 20 | 24,248 | 2,781 | 11,762 | 0 |
31 Dec 19 | 24,234 | 2,762 | 11,797 | 0 |
30 Sep 19 | 24,479 | 9,101 | 12,544 | 0 |
30 Jun 19 | 23,691 | 9,125 | 11,801 | 0 |
31 Mar 19 | 22,444 | 9,132 | 11,036 | 0 |
31 Dec 18 | 20,889 | 9,046 | 10,268 | 0 |
30 Sep 18 | 19,103 | 2,567 | 8,799 | 0 |
30 Jun 18 | 17,062 | 2,436 | 7,921 | 0 |
31 Mar 18 | 15,609 | 2,363 | 7,334 | 0 |
31 Dec 17 | 14,819 | 2,171 | 6,905 | 0 |
30 Sep 17 | 14,491 | 2,115 | 6,680 | 0 |
30 Jun 17 | 14,258 | 1,862 | 6,668 | 0 |
31 Mar 17 | 13,899 | 1,789 | 6,525 | 0 |
31 Dec 16 | 13,543 | 1,637 | 6,493 | 0 |
30 Sep 16 | 13,271 | 1,674 | 6,344 | 0 |
30 Jun 16 | 12,858 | 1,604 | 6,272 | 0 |
31 Mar 16 | 12,507 | 1,575 | 6,084 | 0 |
31 Dec 15 | 12,189 | 1,490 | 5,974 | 0 |
30 Sep 15 | 12,030 | 1,432 | 5,994 | 0 |
30 Jun 15 | 11,124 | 1,447 | 5,483 | 0 |
31 Mar 15 | 10,552 | 1,263 | 5,252 | 0 |
31 Dec 14 | 9,900 | 1,210 | 4,933 | 0 |
30 Sep 14 | 9,205 | 1,074 | 4,457 | 0 |
30 Jun 14 | 8,876 | 951 | 4,366 | 0 |
31 Mar 14 | 8,434 | 886 | 4,287 | 0 |
31 Dec 13 | 7,731 | 809 | 3,945 | 0 |
30 Sep 13 | 8,069 | 868 | 4,174 | 0 |
30 Jun 13 | 6,902 | 815 | 3,621 | 0 |
Quality Earnings: 1177 has high quality earnings.
Growing Profit Margin: 1177's current net profit margins (7.1%) are lower than last year (8.8%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 1177's earnings have declined by 9.7% per year over the past 5 years.
Accelerating Growth: 1177's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 1177 had negative earnings growth (-27.4%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (1.3%).
Return on Equity
High ROE: 1177's Return on Equity (12.1%) is considered low.